「ai safety」の検索結果

Prepares statistical reports for clinical trials following CONSORT 2025, SPIRIT 2025, ICH E9(R1) estimands, and FDA 2023 covariate adjustment guidance. Covers Table 1 generation, analysis populations (ITT/FAS/PP/Safety), the 5 ICH E9(R1) intercurrent-event strategies, MMRM under MAR (mmrm), reference-based MI (rbmi J2R/CR/CIR), Permutt tipping-point sensitivity, and Rubin's-rules vs frequentist variance debate. Use when preparing regulatory submissions, defining estimands, or implementing missing-data sensitivity analyses.

日本語の概要は準備中です。原文の説明を表示しています。

Prepares statistical reports for clinical trials following CONSORT 2025, SPIRIT 2025, ICH E9(R1) estimands, and FDA 2023 covariate adjustment guidance. Covers Table 1 generation, analysis populations (ITT/FAS/PP/Safety), the 5 ICH E9(R1) intercurrent-event strategies, MMRM under MAR (mmrm), reference-based MI (rbmi J2R/CR/CIR), Permutt tipping-point sensitivity, and Rubin's-rules vs frequentist variance debate. Use when preparing regulatory submissions, defining estimands, or implementing missing-data sensitivity analyses.

日本語の概要は準備中です。原文の説明を表示しています。

Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.

日本語の概要は準備中です。原文の説明を表示しています。

Analyze text and images for harmful content with customizable blocklists.

日本語の概要は準備中です。原文の説明を表示しています。

Orchestrator for the eval-output skill suite — evaluate LLM and agent outputs for quality, accuracy, helpfulness, and safety using structured rubrics and LLM-as-judge techniques. Load when the user says "evaluate this output", "score this response", "run an eval", "LLM as judge", "evaluate agent output", "how good is this response", "rate this answer", "eval this", or provides an LLM output that should be assessed for quality. Single entry point for all output evaluation workflows.

日本語の概要は準備中です。原文の説明を表示しています。

Analyze text and images for harmful content with customizable blocklists.

日本語の概要は準備中です。原文の説明を表示しています。

Prepares statistical reports for clinical trials following CONSORT 2025, SPIRIT 2025, ICH E9(R1) estimands, and FDA 2023 covariate adjustment guidance. Covers Table 1 generation, analysis populations (ITT/FAS/PP/Safety), the 5 ICH E9(R1) intercurrent-event strategies, MMRM under MAR (mmrm), reference-based MI (rbmi J2R/CR/CIR), Permutt tipping-point sensitivity, and Rubin's-rules vs frequentist variance debate. Use when preparing regulatory submissions, defining estimands, or implementing missing-data sensitivity analyses.

日本語の概要は準備中です。原文の説明を表示しています。

Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks about hazardous materials (hazmat) transportation under 49 CFR 171-180 — placarding requirements, segregation tables, hazmat employee training (49 CFR 172 Subpart H), Hazmat Safety Permit (HMSP), shipping papers, packaging groups, emergency response phone, security plans, hazmat endorsement on CDL, and bulk vs non-bulk distinctions. Cite specific 49 CFR section.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks about DOT audits, FMCSA compliance reviews, new entrant safety audits (NESA), focused investigations, what auditors actually ask for, audit document checklists, common audit failures, the audit ratings (Satisfactory / Conditional / Unsatisfactory), or how to prepare for an upcoming audit. Cite 49 CFR 385.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks about Environmental Health & Safety (EHS) for trucking — fuel spill response, hazmat release reporting, EPA + state environmental reporting, emergency contact information (CHEMTREC), environmental impairment liability insurance, and how to handle a CMV-related environmental incident. Cite 40 CFR + 49 CFR 174.6.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks about US-Canada cross-border CMV operations — CVOR (Commercial Vehicle Operator's Registration), NSC (National Safety Code), Ontario / Quebec / BC specific rules, US carrier obtaining Canadian operating authority, FAST card for drivers, customs (CBSA), Health Canada hazmat, and how Transport Canada equivalents differ from US FMCSA. Reference USMCA + Transport Canada NSC 14.

日本語の概要は準備中です。原文の説明を表示しています。

Pre-ship safety proof for replacing a live implementation with a canonical one. Use when repointing nodes, tools, or services to a new contract, superseding a schema, retiring a legacy or parallel system, or any 'new way replaces the old way' change. NOT for greenfield or unconsumed additive work.

日本語の概要は準備中です。原文の説明を表示しています。

Perform a diff-scoped, behavior-neutral cleanup of AI-generated slop on the current branch before code review. Use for removing trivial comment, defensive-check, type-laundering, redundant-intermediate, compatibility-shim, or local style drift from the branch diff. Do not use for full correctness or safety review, documentation work handled by technical-documentation or docs-refactor, or repo-wide refactors.

日本語の概要は準備中です。原文の説明を表示しています。

Critical Git safety rules to prevent destructive operations. Use whenever performing git operations, reverting changes, or managing commits. Prevents accidental loss of work.

日本語の概要は準備中です。原文の説明を表示しています。

ドメインモデル、可視性、操作可能性、不変条件、層境界、API 設計に関わる実装時に使う。不正な状態や誤った呼び出し方を、型、関数の境界、ドメイン語彙で表し、正しい使い方が自然になる設計へ寄せるためのスキル。

Master defensive Bash programming techniques for production-grade scripts. Use when writing robust shell scripts, CI/CD pipelines, or system utilities requiring fault tolerance and safety.

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user wants to know what will break if they change something, or needs safety analysis before editing code. Examples: "Is it safe to change X?", "What depends on this?", "What will break?"

日本語の概要は準備中です。原文の説明を表示しています。

Write idiomatic C++ code with modern features, RAII, smart pointers, and STL algorithms. Handles templates, move semantics, and performance optimization. Use PROACTIVELY for C++ refactoring, memory safety, or complex C++ patterns.

日本語の概要は準備中です。原文の説明を表示しています。

GoPlus AgentGuard — AI agent security guard. Automatically blocks dangerous commands, prevents data leaks, and protects secrets. Use when reviewing third-party code, auditing skills, checking for vulnerabilities, evaluating action safety, or viewing security logs.

日本語の概要は準備中です。原文の説明を表示しています。

Decision-theoretic framework for agents embedded within the environments they model and act upon

日本語の概要は準備中です。原文の説明を表示しています。

Review of Cognitive Systems Engineering applications and current practice in safety-critical domains

日本語の概要は準備中です。原文の説明を表示しています。

Design AgentSpeak-style BDI plan libraries with explicit event, context, failure, and authority boundaries. NOT for treating BDI plans as safety approval or guaranteed execution.

日本語の概要は準備中です。原文の説明を表示しています。